1-氧代-1,2,3,4-四氢异喹啉-3-甲酸 | 63586-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1-氧代-1,2,3,4-四氢异喹啉-3-甲酸
• 英文名称: Dl-1-Keto-3-carboxy-1,2,3,4-tetrahydro-isochinolin
• 英文别名: 1-Oxo-1,2,3,4-tetrahydro-3(R,S)-isoquinolinecarboxylic Acid；1-Oxo-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid；1-oxo-3,4-dihydro-2H-isoquinoline-3-carboxylic acid
• CAS: 63586-82-3
• 化学式: C₁₀H₉NO₃
• mdl: MFCD00483631
• 分子量: 191.186
• InChiKey: YXSGIZSINDRUBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  1-氧代-1,2,3,4-四氢异喹啉-3-甲酸 在 10percent Pd/C 硫酸 、 potassium carbonate 、 三溴氧磷 作用下， 以 二苯醚 、 乙腈 为溶剂， 反应 9.5h， 生成 1-溴-3-异喹啉羧酸甲酯
  参考文献：
  名称：

  Synthetic approaches to 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid

  摘要：

  为了研究新的抗肿瘤化合物，我们在此报告了以前未曾描述过的 1-(2-氯苯基)异喹啉-3-羧酸 9 的制备方法。我们研究了从苯乙胺或安非他明出发的两种相关方法，发现都很成功。此外，还利用 2-氯苯硼酸 15 与之前未报道过的 1-溴异喹啉-3-羧酸甲酯 14 之间的铃木交叉偶联，开发出了一种更可靠的合成方法。这一合成路线为采用组合方法研究新的潜在外周苯并二氮杂卓受体配体的核心结构奠定了基础。

  DOI：

  10.1039/b110301f
• 作为产物：
  描述：

  2-溴甲基苯甲酸甲酯 在 氢溴酸 、 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 7.0h， 生成 1-氧代-1,2,3,4-四氢异喹啉-3-甲酸
  参考文献：
  名称：

  Ibotenic acid analogs. Synthesis and biological and in vitro activity of conformationally restricted agonists at central excitatory amino acid receptors

  摘要：

  A number of analogues of ibotenic acid [(RS)-3-hydroxy-5- isoxazoleglycine ] were synthesized; they were tested as excitants on neurons in the cat spinal cord, by using microelectrophoretic techniques, and as inhibitors of the binding of kainic acid (KA) in vitro, by using synaptic membranes prepared from rat brains. The excitatory effects of the 3- isoxazolol amino acids (RS)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5, 4-c]pyridine-7-carboxylic acid (4, 7- HPCA ), (RS)-alpha-amino-3-hydroxy-5,6-dihydro-4H- cyclohept [1,2-d] isoxa zole - 8-propionic acid (8, 8- AHCP ), (RS)-alpha-amino-3- hydroxy-7,8-dihydro-6H- cyclohept [1,2-d] isoxazole -4-propionic acid (12, 4- AHCP ), and (RS)-alpha-(methylamino)-3-hydroxy-5-methyl- 4- isoxazolepropionic acid (15, N-Me-AMPA) were shown to be sensitive to (S)-glutamic acid diethyl ester (GDEE), an antagonist at quisqualic acid ( QUIS ) receptors, and insensitive to (RS)-2-amino-5-phosphonovaleric acid ( 2APV ), an antagonist at N-methyl-(R)-aspartic acid (NMDA) receptors. The compounds 4 and 12 proved to be particularly potent agonists at the former class of receptor, assumed to represent physiological glutamic acid receptors. The amino acids (RS)-beta-(2-carboxyphenyl)alanine (19), an analogue of 12, and (RS)-2-(3-carboxyphenyl) glycine were weak GDEE-sensitive excitants with potencies comparable with that of 8. All of the compounds were tested as inhibitors of KA binding. With the exception of 12 and 19, which showed very low affinity for the KA binding sites, the compounds studied were inactive in this in vitro test system.

  DOI：

  10.1021/jm00371a005

文献信息

• 1,2-Benzothiazine 1,1-Dioxide P₂−P₃ Peptide Mimetic Aldehyde Calpain I Inhibitors
  作者：Gregory J. Wells、Ming Tao、Kurt A. Josef、Ron Bihovsky

  DOI：10.1021/jm010178b

  日期：2001.10.1

  A series of peptide mimetic aldehyde inhibitors of calpain I was prepared in which the P(2) and P(3) amino acids were replaced by substituted 3,4-dihydro-1,2-benzothiazine-3-carboxylate 1,1-dioxides. The effect of 2, 6, and 7-benzothiazine substituents and the P(1) amino acid was examined. Potency of these inhibitors, 15c-p, against human recombinant calpain I is particularly dependent upon the 2-substituent

  制备了一系列钙蛋白酶I的肽模拟醛抑制剂，其中P（2）和P（3）氨基酸被取代的3,4-二氢-1,2-苯并噻嗪-3-羧酸1,1-二氧化物取代。检查了2、6和7-苯并噻嗪取代基和P（1）氨基酸的作用。这些抑制剂15c-p对人重组钙蛋白酶I的效力特别取决于2-取代基，其中甲基和乙基通常比氢，异丙基，异丁基或苄基更有效。15m的更有效的非对映异构体在3,4-二氢-1,2-苯并噻嗪的3位上具有（S）绝对构型。该系列中最佳抑制剂的效能（IC（50）= 5-7 nM）与在P（2）处带有L-Leu或L-Val残基的常规N-苄氧基羰基二肽醛抑制剂的性能相比具有优势。
• Modulators of serotonin receptors
  申请人：Wacker A. Dean

  公开号：US20050080074A1

  公开（公告）日：2005-04-14

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• Design, Synthesis, and In Vitro Evaluation of Potential West Nile Virus Protease Inhibitors Based on the 1-Oxo-1,2,3,4-tetrahydroisoquinoline and 1-Oxo-1,2-dihydroisoquinoline Scaffolds
  作者：Dengfeng Dou、Prasanth Viwanathan、Yi Li、Guijia He、Kevin R. Alliston、Gerald H. Lushington、Joshua D. Brown-Clay、R. Padmanabhan、William C. Groutas

  DOI：10.1021/cc100091h

  日期：2010.11.8

  The 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline and 1-Oxo-1, 2-dihydroisoquinoline scaffolds were utilized in the design and solution phase synthesis of focused libraries of compounds for screening against West Nile Virus (WNV) protease. Exploratory studies have led to the identification of a WNV protease inhibitor (a 1-oxo-1, 2-dihydroisoquinoline-based derivative, 12j) which could potentially serve as

  1-oxo-1, 2, 3, 4-tetrahydroisoquinoline 和 1-Oxo-1, 2-dihydroisoquinoline 支架用于设计和液相合成重点化合物库，用于筛选西尼罗河病毒 (WNV) 蛋白酶。探索性研究导致鉴定了一种 WNV 蛋白酶抑制剂（一种基于 1-oxo-1, 2-dihydroisoquinoline 的衍生物，12j），它可能作为一个潜在的先导优化活动的跳板。鉴定出的命中对一组哺乳动物丝氨酸蛋白酶没有任何抑制活性。
• 1-Oxo-1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid derivatives
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：US04537967A1

  公开（公告）日：1985-08-27

  The following new isocarbostyryl derivatives represented by the general formula [I]: ##STR1## wherein R.sub.1 is a hydrogen atom or a lower alkyl group, are provided, said derivatives having excellent angiotensin converting enzyme inhibitory activity with expectations therefore being as a hypotensor, and prepared by solvolysis of a compound of the following general formula [II]: ##STR2## wherein R.sub.1 is the same as defined above, R.sub.2 is an acyl group, and R.sub.3 is a hydrogen atom, an alkyl group or an aralkyl group.

  以下由一般式[I]表示的新异芳烯基衍生物提供，其中R1是氢原子或较低的烷基基团，这些衍生物具有出色的血管紧张素转换酶抑制活性，因此有望作为降压剂，通过以下一般式[II]的化合物的溶解制备：其中R1与上述定义相同，R2是酰基基团，R3是氢原子、烷基或芳基烷基。
• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。